BRIEF-Ipsen says EMA accepts marketing authorization application for telotristat etiprate

* Ipsen announces the acceptance by the european medicines agency of the marketing authorization application for telotristat etiprate to treat carcinoid syndrome caused by neuroendocrine tumors, in combination with somatostatin analogues